溶瘤腺病毒作为癌症基因治疗载体的研究进展及安全性评价  

Oncolytic Adenovirus as a Vector of Gene Therapy for Cancer Progression and Safety Evaluation

作　　者：何婉婉[1] 周立[1] 刘涛[1] 阮江星[1] 何滨霞[1] 李阿荣[1] 王毅刚[1] 

机构地区：[1]浙江理工大学生命科学学院,新元医学与生物技术研究所,杭州310018

出　　处：《中国细胞生物学学报》2013年第9期1386-1391,共6页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:81272687);浙江省自然科学基金(批准号:Z13H160020);浙江省大学生科技创新活动计划暨新苗人才计划(批准号:2012R406026)资助的课题~~

摘　　要：腺病毒因具有易感染性、宿主范围广、毒性低、容纳量大、非整合性等特点而成为基因转移中最具前景的基因载体之一,并且被广泛地改造成各种类型的溶瘤腺病毒应用于癌症基因治疗的研究之中。溶瘤腺病毒是目前基因治疗中最热门的研究途径之一,其安全性也随之成为另一个焦点问题。由此,该文将对溶瘤腺病毒作为癌症基因治疗载体的研究进展及生物安全性评价作一综述。Adenovirus is one of the most promising gene vectors in gene transfer by the reason of susceptibility, wide host ranges, low toxicity, high capacity, non-integrated features and so on. Now it has been widely transformed into various types of oncolytic adenovirus in the study of cancer gene therapy. Oncolytic adenoviruses is one of the most popular avenues in the study of gene therapy, so its safety has become another focus. This review focuses on the overall research progress and biosafty evaluation of oncolytic adenoviruses as cancer gene therapy vectors.

关 键 词：溶瘤腺病毒 基因治疗 安全性评价 

分 类 号：R730.5[医药卫生—肿瘤]